The pattern of anti-IL-6 versus non-anti-IL-6 biologic disease modifying anti-rheumatic drugs use in patients with rheumatoid arthritis in Wales, UK: a real-world study using electronic health records
2024

Use of Anti-IL-6 Biologics in Rheumatoid Arthritis Patients in Wales

Sample size: 4922 publication 10 minutes Evidence: moderate

Author Information

Author(s): Roxanne Cooksey, Jonathan Kennedy, Muhammad Rahman, Sinead Brophy, Ernest Choy

Primary Institution: Cardiff University

Hypothesis

What factors are associated with the initiation and discontinuation of anti-IL-6 biologic DMARDs compared to non-anti-IL-6 biologics in rheumatoid arthritis patients?

Conclusion

Comorbidities, history of infection, and kidney disease were associated with choosing anti-IL-6 bDMARDs in biologic-naïve RA patients in Wales.

Supporting Evidence

  • 95.7% of patients received conventional synthetic DMARDs.
  • 36.2% of patients were treated with bDMARDs.
  • 6.5% of biologic-naïve patients were treated with anti-IL-6 bDMARDs.
  • Treatment discontinuation was higher in non-anti-IL-6 bDMARD-treated patients.

Takeaway

Doctors in Wales found that patients with certain health issues are more likely to be given a specific type of medicine for arthritis, and those patients tend to stick with their treatment better.

Methodology

A retrospective cohort study using electronic health records from the Secure Anonymised Information Linkage Databank, analyzing treatment initiation, discontinuation, and clinical outcomes.

Potential Biases

Potential underpowering to detect associations due to low numbers of patients on anti-IL-6 bDMARDs.

Limitations

The cohort may not represent early or less severe rheumatoid arthritis patients, and the absence of certain clinical data may limit findings.

Participant Demographics

Mean age of 62 years, 71.6% female, mean disease duration of 6.3 years.

Statistical Information

P-Value

p<0.05

Confidence Interval

95% CI 1.1, 17.8

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1093/rap/rkae140

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication